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Background: Using the Surveillance, Epidemiology, and End Results—Medicare database, a substantial in-
crease was found in the use of positron emission tomography (PET) scans after 2004 in differentiated thyroid
cancer (DTC) patients. The reason for the increased utilization of the PET scan was not clear based on available
the data. Therefore, the indications for and outcomes of PET scans performed at an academic institution were
evaluated.
Methods: A retrospective cohort study was performed of DTC patients who underwent surgery at the University
of Michigan Health System from 2006 to 2011. After identifying patients who underwent a PET scan, indi-
cations, rate of positive PET scans, and impact on management were evaluated. For positive scans, the location
of disease was characterized, and presence of disease on other imaging was determined.
Results: Of the 585 patients in the cohort, 111 (19%) patients had 200 PET scans performed for evaluation of
DTC. Indications for PET scan included: elevated thyroglobulin and negative radioiodine scan in 52 scans
(26.0%), thyroglobulin antibodies in 13 scans (6.5%), rising thyroglobulin in 18 scans (9.0%), evaluation of
abnormality on other imaging in 22 scans (11.0%), evaluation of extent of disease in 33 scans (16.5%), follow-
up of previous scan in 57 scans (28.5%), other indications in two scans (1.0%), and unclear indications in three
scans (1.5%). The PET scan was positive in 124 studies (62.0%); positivity was identified in the thyroid bed on
25 scans, cervical or mediastinal lymph nodes on 105 scans, lung on 28 scans, bone on four scans, and other
areas on 14 scans. Therapy following PET scan was surgery in 66 cases (33.0%), chemotherapy or radiation in
23 cases (11.5%), observation in 110 cases (55.0%), and palliative care in one case (0.5%). Disease was
identifiable on other imaging in 66% of cases. PET scan results changed management in 59 cases (29.5%).
Conclusions: In this academic medical center, the PET scan was utilized in 19% of patients. Indications for the
PET scan included conventional indications, such as elevated thyroglobulin with noniodine avid disease, and
more controversial uses, such as evaluation of extent of disease or abnormalities on other imaging tests. PET
scan results changed management in about 30% of cases.
Introduction
The incidence of differentiated thyroid cancer(DTC) has been increasing progressively over the past
two decades, with the largest increase in small, low-risk
tumors (1,2). Conventional therapies have included total
thyroidectomy and radioactive iodine treatment to reduce
mortality and risk of recurrence (3). While the risk of death
due to thyroid cancer is low in DTC patients, the risk of
recurrence is a significant concern to the providers that follow
these patients long term (4). Therefore, a variety of imag-
ing techniques have been employed to detect persistent
or recurrent disease in the postoperative setting. Several
frequently utilized imaging modalities are neck ultrasound,
radioactive iodine scan, computed tomography (CT) scan,
and positron emission tomography (PET) scan (5,6).
The PET scan is the newest imaging modality used in the
postoperative surveillance of DTC patients. As such, there
remains significant controversy and uncertainty with regards
to the optimal way to integrate it into practice (7–10). Pre-
vious studies have shown the ability of the PET scan to lo-
calize disease already thought to be present because of
detectable thyroglobulin levels (11,12). This has been the
most generally accepted indication for performing a PET
scan. However, others have argued that PET scanning adds
little beyond neck ultrasound and CT scan of the neck and
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chest in this scenario (13). Though less generally accepted,
PET scanning has also been utilized in other situations, such
as in patients with elevated antithyroglobulin antibodies
(14,15).
The authors previously showed an increase of up to 33.4-
fold in the use of PET scans in the postoperative surveillance
of DTC patients after 2004 using the Surveillance, Epide-
miology, and End Results (SEER)—Medicare database (16).
However, this large population-based database lacked sig-
nificant details to determine the indications for the PET scans
being performed or the results of the test, and how they are
affecting management. Therefore, a single-institution, ret-
rospective cohort study was performed of DTC patients seen
at the University of Michigan to determine the rate of utili-
zation of and the indications for PET scans, as well as and
eventual changes in management based on PET scan results.
Methods
Data source and study population
The University of Michigan Thyroid Cancer Database, a
project of the Michigan Endocrine Oncology Repository
(HUM00024461), includes 668 patients who underwent sur-
gery at the University of Michigan and had a pathologically
confirmed diagnosis of thyroid cancer between 2006 and
2011. It includes demographic, surgical, pathologic, radio-
graphic, and thyroid cancer recurrence data entered into a
REDCap database (17). Using this database, first only those
individuals with DTC were identified, defined as International
Classification of Disease for Oncology: papillary, follicular,
or Hu¨rthle cell cancer (18). In total, 585 patients with DTC
were included in the analysis. Then those patients who un-
derwent a PET scan at the authors’ institution for evaluation of
thyroid cancer were identified. Additionally, patients who had
a PET scan at an outside institution submitted to the authors’
radiology department for review were included. All PET
scans were obtained based on the clinicians’ opinion that a
PET scan would assist with the management of their patient.
Any patient who had an initial PET scan for an indication
other than thyroid cancer was excluded from the analysis, as
this first PET scan was felt to influence the decision to obtain
additional PET scans. Approval for the study was granted by
the University of Michigan Institutional Review Board.
Measures
Patient demographics were obtained, including age, sex,
and race/ethnicity. Race/ethnicity was categorized as white,
Asian, black, and other. Primary tumor characteristics were
also obtained from pathologic specimens, when available.
These characteristics included: histology, tumor size, pres-
ence of capsular invasion, extrathyroidal extension, presence
of lymph node metastasis, and American Joint Commission
on Cancer stage (19).
The number of PET scans that were performed in each
patient was identified. For each PET scan, the indication for
the PET scan was determined, categorized as follows: ele-
vated thyroglobulin with noniodine avid disease, positive
thyroglobulin antibodies, rising thyroglobulin, evaluation of
an abnormality on another imaging test, evaluation of extent
of disease, follow-up of a previous PET scan, other indica-
tions, or unknown indication. If more than one indication was
present, the documentation of the ordering physician was
reviewed to determine their reason for ordering the test. For
example, if a patient had a negative radioactive iodine scan
with an elevated thyroglobulin that was rising, and the phy-
sician documented that the reason for ordering the PET was
the increasing thyroglobulin, the indication for that PET scan
was categorized as rising thyroglobulin. The method of
stimulation was classified as recombinant thyrotropin (TSH),
hypothyroidism, not stimulated, or unknown. Each PET scan
was characterized as positive or negative for disease, verified
by surgical pathology when available. If positive, the location
of the disease was identified as thyroid bed, cervical and/or
mediastinal lymph nodes, lungs, bone, or other. If other im-
aging was performed, it was ascertained whether the abnor-
mality was identifiable on other imaging.
The management plan after each PET scan was determined:
surgery, chemotherapy or radiation (including tyrosine kinase
inhibitors and radioactive iodine therapy), observation, or
palliative care. Finally, the study identified whether the PET
scan changed the management of the patient. A PET scan was
considered to have changed the management of the patient if
the PET scan identified disease that was not previously
known and resulted in an intervention, if the PET scan re-
sulted in the decision to not pursue a specific intervention, or
if the PET scan changed the extent of a planned surgery
because of additional disease identified. For example, in a
patient with an elevated thyroglobulin and nonradioiodine
avid disease who had a positive PET scan and underwent
surgical excision of lymph nodes in the neck, PET would be
considered to have changed management. Additionally, if
disease was already identified by another imaging modality
but PET imaging showed additional disease that led to a
change in the planned surgical procedure (reoperative central
neck dissection vs. modified radical neck dissection), that
was considered to have changed management. If a patient had
an elevated thyroglobulin and would have empirically been
treated with radioactive iodine, but treatment was withheld
because of fluorodeoxyglucose (FDG) uptake on PET scan-
ning, this was considered to be a change in management. If
patients underwent chemotherapy (including tyrosine kinase
inhibitors) or radiation therapy due to disease found on PET
imaging, that was also considered a change in management.
Finally, one patient was enrolled in hospice due to worsening
disease on PET scanning, and that was considered a change in
management.
For each PET scan performed, when available, the
patient’s thyroglobulin level at that time was recorded.
Thyroglobulin was considered stimulated if obtained
under recombinant thyroid stimulating hormone or thyroid
hormone withdrawal. Otherwise, it was considered un-
stimulated. If thyroglobulin antibodies were present, the
thyroglobulin was considered invalid and not included in
the analysis.
Statistical analysis
For continuous variables, such as patient age and thyro-
globulin levels, median and interquartile ranges were calcu-
lated. For categorical variables, such patient sex and race/
ethnicity, the number and percent of patients and/or scans
within each category was determined. For the location of
disease on PET scan, more than one location may have been
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present on a scan. For example, if a patient had disease seen in
the neck and lung, the PET scan would be considered positive
in both those locations. Therefore, only the number of scans
with disease in each location was determined, and the total
may be more than the number of positive scans.
To determine if thyroglobulin levels could predict the
presence of disease on PET scan, scans were categorized as
positive or negative. Median stimulated and unstimulated
thyroglobulin levels for each group were calculated, as well
as the interquartile range. The two groups were compared for
statistical significance using a two tailed t-test. A p-value of
<0.05 was considered significant.
To examine pretest characteristics that increased the like-
lihood of PET imaging changing management, a chi-square
analysis was performed with change in management as the
outcome. The variables that were included in the analysis
were type of stimulation, indication for PET scan, stimulated
thyroglobulin, and unstimulated thyroglobulin. For the pur-
poses of this analysis, thyroglobulin levels were characterized
as <10 ng/nL, 10–30 ng/mL, and >30 ng/mL. A p-value of
< 0.05 was considered significant.
Results
Of the 585 patients in the cohort, 111 (19%) patients un-
derwent at least one PET scan. In total, 200 PET scans were
identified that were performed for evaluation of DTC. The
demographics and initial tumor characteristics of patients
who underwent PET scan are summarized in Table 1. The
median follow-up time was five years, with a minimum of
three months and a maximum of 20 years. Sixty patients
(54.1%) had only one PET scan, 28 patients (25.2%) under-
went two PET scans, 12 patients (10.8%) underwent three
PET scans, seven patients (6.3%) underwent four PET scans,
three patients (2.7%) underwent five PET scans, and one
patient (0.9%) had more than five PET scans.
Indications for all PET scans included: elevated thyro-
globulin and negative radioactive iodine scan in 52 scans
(26.0%), positive thyroglobulin antibodies in 13 scans (6.5%),
rising thyroglobulin in 18 scans (9.0%), evaluation of an
abnormality on other imaging test in 22 scans (11%), eval-
uation of extent of disease in 33 scans (16.5%), follow-up of a
previous scan in 57 scans (28.4%), other indications in two
scans (1.0%), and unknown indications in three scans (1.5%).
In total, 97 scans (48.5%) were done using recombinant
thyroid stimulating hormone, 21 scans (10.1%) were per-
formed in a hypothyroid state, 64 scans (32%) were com-
pleted without stimulation, and 18 scans (9%) had unknown
stimulation.
A total of 124 (62%) of the PET scans were positive and 76
scans (38.0%) were negative. A total of 25 scans had uptake
present in the thyroid bed, 105 scans had an abnormality in
the cervical and/or mediastinal lymph nodes, 28 scans
showed uptake in the lung, four scans showed bone uptake,
and 14 scans showed uptake in other areas. Management after
PET scan was surgery in 66 cases (33.0%), chemotherapy or
radiation in 23 cases (11.5%), observation in 110 cases
(55.0%), and palliative care in one case (0.5%). The abnor-
mality was identifiable on other imaging in 82 of 98 cases
where other imaging was done (83%). PET changed man-
agement in 59 cases (29.5%) overall, did not change man-
agement in 138 cases (69.0%), and was unclear in three cases
(1.5%). The indications and outcomes of initial PET scans
and subsequent PET scans performed in the study are sum-
marized in Table 2.
The median stimulated thyroglobulin was 10.95 ng/mL
(interquartile range 2.7–47.55 ng/mL). The stimulated thyro-
globulin was <10 ng/mL prior to 53 PET scans and unde-
tectable prior to 15 PET scans. The median unstimulated
thyroglobulin was 1.85 ng/mL (interquartile range 0.5–
11.675 ng/mL). Thyroglobulin values were missing or anti-
bodies were present prior to 48 scans (24.0%). The median
stimulated thyroglobulin in patients with a positive PET scan
was 26.4 ng/mL (interquartile range 7.9–141 ng/mL) and was
3.45 ng/mL (interquartile range 0.75–15.55 ng/mL) in patients
Table 1. Demographics of Differentiated Thyroid
Cancer Patients who Underwent PET Scan
Age, years (median, interquartile range) 51 (37–60.5)
Sex
Male 42 (38%)
Female 69 (62%)
Race/ethnicity
White 102 (91.8%)
Asian 6 (5.4%)
African American 2 (1.8%)
Other 1 (1%)
Histology
Papillary 104 (92.8%)
Follicular 3 (2.7%)
Hu¨rthle cell 4 (3.6%)
Stage at diagnosis
I 51 (45.9%)
II 2 (1.8%)
III 19 (17.1%)
IV 31 (27.9%)
Unknown 8 (7.2%)
Size
<1.0 cm 9 (8.1%)
1.0–1.9 cm 29 (26.1%)
2.0–3.9 cm 35 (31.5%)
‡ 4.0 cm 23 (20.7%)
Unknown 15 (13.5%)
Capsular invasion
Present 61 (55.0%)
Absent 22 (19.8%)
Unknown 28 (25.2%)
Extrathyroidal extension
Present 58 (52.3%)
Absent 28 (25.2%)
Unknown 25 (22.5%)
Lymph node metastasis
Present 70 (63.1%)
Absent 5 (4.5%)
Unknown 36 (32.4%)
Number of PET scans
1 60 (54.1%)
2 28 (25.2%)
3 12 (10.8%)
4 7 (6.3%)
5 3 (2.7%)
6 + 1 (0.9%)
PET, positron emission tomography.
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with a negative PET scan ( p = 0.036). While these groups
were statistically different, there was no thyroglobulin level
that predicted a positive scan. Scatter plots of the stimulated
(1a) and unstimulated (1b) thyroglobulin values are shown
in Figure 1.
The type of stimulation used in the PET scans did not
significantly affect the likelihood of PET imaging to change
management ( p= 0.246). Progressively higher unstimulated
and stimulated thyroglobulin—stratified into <10 ng/dL, 10–
30 ng/mL, and >30 ng/mL—increased the likelihood that PET
scanning would change management ( p= 0.005 and p= 0.004,
respectively). Additionally, it was found that PET scans had
the greatest utility when evaluating a rising thyroglobulin,
where 67% of the scans changed management, compared
with 15% of scans changing management if they are per-
formed for follow-up of a previous study ( p = 0.046).
However, the number was small in certain subgroups of
the indication analysis (<5). Hence, the results should be
interpreted with caution. The corresponding results are
shown in Table 3.
Discussion
In the present study, a high rate of PET utilization was
observed at the authors’ institution, with almost 20% of pa-
tients with DTC undergoing at least one PET scan. The most
common indication for the initial PET scan was an elevated
thyroglobulin with noniodine avid disease. However, a large
proportion of patients was also seen having an initial PET
scan for indications such as evaluation of extent of disease or
evaluation of an abnormality that was seen on another
Table 2. Characteristics and Outcomes
of PET Scans Performed
Initial PET
scan (n = 111)
Follow-up PET
scan (n= 89)
Indication for PET scan
+TG with negative
131I scan
44 (39.6%) 8 (8.9%)
TG antibodies 9 (8.1%) 4 (4.5%)
Rising TG 5 (4.5%) 13 (14.6%)
Abnormality on
other imaging test
19 (17.2%) 3 (3.4%)
Evaluation of
extent of disease
30 (27.0%) 3 (3.4%)
Follow-up of
previous PET
N/A 57 (64.0%)
Other 1 (0.9%) 1 (1.1%)
Unknown 3 (2.7%) 0 (0.0%)
Method of stimulation
rhTSH 46 (41.4%) 51 (57.3%)
Hypothyroid 17 (15.3%) 4 (4.5%)
Unstimulated 35 (31.5%) 64 (32.5%)
Unknown 13 (11.7%) 5 (5.6%)
PET positive vs. negative
Negative 40 (36.0%) 36 (40.5%)
Positive 71 (64.0%) 53 (59.5%)
Location of abnormality*
Thyroid bed 18 7
Neck 59 46
Lung 11 17
Bone 2 2
Other 8 6
Abnormality present on other imaging
Yes 53 (74.6%) 29 (54.7%)
No 8 (11.3%) 8 (15.1%)
Unknown 10 (14.1%) 16 (30.2%)
Management following PET
Surgery 50 (45.0%) 16 (18.0%)
Chemo or radiation
(includes 131I)
9 (8.1%) 14 (15.7%)
Observation 52 (46.8%) 58 (65.2%)
Palliation 0 (0%) 1 (1.1%)
PET changed management**
Yes 34 (30.6%) 25 (28.1%)
No 76 (68.5%) 138 (69.6%)
Unclear 1 (0.9%) 2 (2.2%)
*Patient may have disease in more than one location.
**PET was considered to have changed management if it
identified disease that was not previously identified and resulted
in an intervention, led to cancelation of a previously planned
intervention, or changed the extent of a previously planned surgery.
TG, thyroglobulin; rhTSH, recombinant human thyrotropin.
FIG. 1. (A) Stimulated thyroglobulin levels in positive
versus negative positron emission tomography (PET) scans.
(B) Unstimulated thyroglobulin levels in positive versus
negative PET scans.
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imaging study. Overall, the most common indication for any
PET scan was follow-up of another PET scan. Additionally, it
was observed that most disease identified was localized to the
cervical or mediastinal lymph nodes and was often visible on
other imaging modalities, such as neck ultrasound or CT. It
was found that the PET scan changed management in ap-
proximately 30% of cases.
Much of the existing literature surrounding PET scan use
for the surveillance of DTC occurs in the setting of an ele-
vated thyroglobulin with noniodine avid disease. For this
indication, the PET scan has been shown to be capable of
identifying disease with a sensitivity of about 90% and
specificity of about 80% (11,12,20). Razfar et al. evaluated
the likelihood that a PET scan would change management in
this scenario, and found that a PET scan changed the treatment
plan in 28.2% of cases, which is similar to the present findings
(21). There is a smaller body of literature describing the use of
the PET scan for initial staging in intermediate- to high-risk
patients with conflicting conclusions regarding its utility
(10,22). Others have described the use of the PET scan in the
evaluation of patients with persistently elevated thyroglobulin
antibodies, and found about half of patients have disease
identified on a PET scan (14,15). In the present study, it was
found that evaluation of elevated thyroglobulin antibodies with
a PET scan was as likely to change management as evaluating
elevated thyroglobulin the setting of noniodine avid disease.
While it has been shown to have utility in certain clinical
scenarios, PET scans are expensive and expose the patient to
radiation (23,24). Therefore, the clinician must use their
judgment to determine when they should be utilized. The
lesions identified on PET scans could also be found on other
imaging modalities, including ultrasound or CT, in 82 of 98
patients. The present study found that the majority of disease
that was detected on a PET scan was in the cervical and
mediastinal lymph nodes. In the preoperative setting, ultra-
sound has a higher sensitivity to detect abnormal cervical
lymph nodes than PET/CT (25). Given the increased cost and
radiation exposure of PET/CT compared with ultrasound, its
use should be reserved for indications for which there is
strong evidence supporting its utility.
Previous studies have examined the correlation between
PET positivity with stimulated serum thyroglobulin level.
Collectively, these previous studies suggest that PET/CT
may be most helpful in patients with stimulated thyroglobulin
levels >20–30 ng/mL (15,26,27). The present study also
shows a correlation between increasing stimulated thyro-
globulin levels and PET positivity, but there was no thyro-
globulin level that predicted presence or absence of disease.
The present results do suggest that PET scans done in patients
with low thyroglobulin levels are unlikely to change man-
agement and should be avoided.
The use of stimulation for PET scanning has been evaluated
with somewhat mixed results. Petrich et al. found that the
number of positive scans, as well as the number of lesions and
standardized uptake values (SUV), increased with the use of
rhTSH stimulation (28). In contrast, Leboulleux et al. found
that the number of positive scans did not increase, but the
number of identified lesions did increase after stimulation with
rhTSH; the increased number of lesions changed management
in about 6% of cases (29). Despite studies showing that sen-
sitivity of PET imaging improves under TSH stimulation, a
high proportion of PET scans being done without stimulation
Table 3. Correlates of PET Scan Resulting in Change of Management
Did PET change management?
Yes No Unclear p-Value*
Method of stimulation
rhTSH 34 (35.4%) 60 (62.5%) 2 (2.0%) 0.246
Hypothyroid 5 (23.8%) 16 (76.2%) 0 (0.0%)
Not stimulated 14 (19.4%) 57 (79.2%) 1 (1.3%)
Unknown 8 (42.1%) 11 (57.9%) 0 (0%)
Indication for PET scan
+TG with negative 131I scan 17 (32.7%) 34 (65.4%) 1 (1.9%) 0.046
TG antibodies 5 (38.5%) 8 (61.5%) 0 (0.0%)
Rising TG 12 (66.7%) 6 (33.3%) 0 (0.0%)
Abnormality on other imaging test 8 (34.8%) 15 (65.2%) 0 (0.0%)
Evaluation of extent of disease 7 (19.4%) 29 (80.6%) 0 (0.0%)
Follow-up of previous PET 9 (15.5%) 47 (81.0%) 2 (3.4%)
Other 3 (50.0%) 3 (50.0%) 0 (0.0%)
Unknown 1 (33.3%) 2 (66.7%) 0 (0.0%)
Stimulated TG
< 10 ng/mL 7 (14.0%) 43 (86.0%) 0.005
10–30 ng/mL 9 (42.9%) 12 (57.1%) 0 (0.0%)
> 30 ng/mL 18 (52.9%) 15 (44.1%) 1 (2.9%)
Not checked or positive antibodies 19 (33.3%) 36 (63.2%) 2 (3.5%)
Unstimulated TG
< 10 ng/mL 20 (21.7%) 72 (78.3%) 0 (0.0%) 0.004
10–30 ng/mL 13 (56.5%) 10 (43.5%) 0 (0.0%)
> 30 ng/mL 8 (50.0%) 7 (43.8%) 1 (6.2%)
Not checked or positive antibodies 19 (33.3%) 36 (63.2%) 2 (3.5%)
*p for v2 test.
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was observed in the present study. However, in this study, a
significant effect of stimulation on the likelihood of PET im-
aging to change management was not seen.
The present study does have several important limitations
that should be noted. It is a single center study, and therefore
it may not capture imaging that was done at other centers. In
order to minimize this limitation, imaging that was done at
other centers but read by our radiology department was in-
cluded. Second, as an academic referral center, we may see a
higher proportion of high risk patients compared with those
practicing in the community. Therefore, the applicability to
smaller community practices may be limited. This is a ret-
rospective study, which inherently has the issue of missing
data. However, in the present study, missing data were low
for the variables of interest, such as PET indications. Ad-
ditionally, the categorization of indications for PET scan can
be subjective, especially when distinguishing between subtle
differences in indication, such as elevated thyroglobulin with
negative radioactive iodine scan versus rising thyroglobulin.
Nonetheless, it was clear when a PET scan was being ordered
for an indication such as evaluation of extent of disease or an
abnormality on another imaging test. Finally, with regards to
the presence of disease on other imaging studies, providers
may be more likely to identify disease with other imaging
modalities if they know results of the patient’s PET scan.
Despite these limitations, there are several strengths that
make this study unique and contribute to the knowledge
regarding PET scan use. First, this study includes a large
population of patients compared with other studies utilizing
PET scans. A real-world experience with PET scan is also
reported. Much of the prior work has been done in a pop-
ulation of patients with elevated thyroglobulin and non-
iodine avid disease, with limited information on the use of
PET scans in other scenarios. In addition, the present data
suggest that a significant number of PET scans are being
done for indications other than noniodine avid disease.
Finally, ability to identify disease on other imaging was
evaluated, which is often omitted from other studies. When
it has been evaluated, results were similar to the present
study (13,15).
The rising incidence of low-risk thyroid cancer is changing
treatment paradigms (30). Increasingly, management is being
driven by risk assessment, and a ‘‘one size fits all’’ approach
to thyroid cancer treatment is no longer recommended (31).
The same should be true for post-treatment surveillance. The
choice of imaging modality should be tailored toward the
patient’s risk, the clinical suspicion for recurrent or persistent
disease, and the serum thyroglobulin. The present study
suggests that the PET scan is most helpful in patients with
higher thyroglobulin levels in the setting of a negative
radioiodine scan or when evaluating a rising thyroglobulin
and that routine follow-up of a previous scan is least likely to
change management. In addition, attention should be paid to
cost-effectiveness and radiation exposure. Future research
needs to investigate whether use of an imaging modality can
affect patient morbidity and mortality, rather than simply
identifying recurrent or persistent thyroid cancer.
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